BioCentury
ARTICLE | Company News

U.K. firm licenses trial success prediction tool from Molecular Health

January 11, 2019 6:31 PM UTC

Daten Capital LLP (London, U.K.) received exclusive rights from Molecular Health (Heidelberg, Germany) to Molecular Health Predict (MH Predict), an AI-based tool to predict the outcome of clinical trials, for use in the financial industry.

Molecular Health will receive an undisclosed annual license fee, plus success-based payments...